| Pharmaceutical Information |
| Drug Name |
Ropinirole |
| Drug ID |
BADD_D01966 |
| Description |
Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547].
In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole [A35711]. |
| Indications and Usage |
For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N04BC04 |
| DrugBank ID |
DB00268
|
| KEGG ID |
D08489
|
| MeSH ID |
C046649
|
| PubChem ID |
5095
|
| TTD Drug ID |
D0R9EQ
|
| NDC Product Code |
43353-267; 55111-727; 43353-265; 0228-3660; 46708-262; 60429-822; 10135-677; 0228-3659; 68462-259; 0378-5505; 10135-676; 16729-238; 43353-258; 50090-4684; 55111-662; 50090-5167; 71335-1188; 71335-0064; 60429-818; 50090-4803; 10135-673; 68462-258; 43353-266; 68462-254; 46708-265; 71335-1231; 62332-109; 68462-257; 0228-3640; 0378-5502; 46708-264; 58032-1011; 0781-5786; 60429-821; 0378-5504; 16729-237; 10135-678; 70518-2439; 10135-679; 55111-659; 50090-2068; 71335-1982; 16729-233; 46708-266; 72189-222; 16729-232; 0378-5501; 0378-5503; 68462-253; 60429-817; 60429-823; 68462-255; 16729-235; 62332-108; 55111-661; 70518-2750; 60429-819; 55111-728; 0378-5525; 0781-5784; 0228-3658; 16729-234; 63629-8123; 10135-674; 10135-675; 68462-256; 61919-780; 0378-5550; 62332-110; 60429-820; 71335-1167; 62332-107; 0228-3661; 16729-236; 46708-263; 0781-5780; 0781-5788; 62332-111; 0781-5782 |
| Synonyms |
ropinirole | 4-(2-(di-n-propylamino)ethyl)-2(3H)-indolone | ropinirol | SK&F 101468 | SKF 101468 | SK&F-101,468 | Requip | ropinirole hydrochloride |
|
| Chemical Information |
| Molecular Formula |
C16H24N2O |
| CAS Registry Number |
91374-21-9 |
| SMILES |
CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1 |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Disease susceptibility | 08.01.03.066 | 0.000427% | | Not Available | | Limbic encephalitis | 17.06.05.004; 16.32.01.007; 10.04.10.013 | 0.000854% | | Not Available |
|
|
|
